NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $23.37 -0.07 (-0.30%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$23.37 0.00 (0.00%) As of 05/21/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Assertio Stock (NASDAQ:ASRT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Assertio alerts:Sign Up Key Stats Today's Range$23.36▼$23.4550-Day Range$11.50▼$23.4452-Week Range$8.61▼$23.46Volume281,812 shsAverage Volume478,193 shsMarket Capitalization$150.97 millionP/E RatioN/ADividend YieldN/APrice Target$22.65Consensus RatingReduce Company Overview Assertio Therapeutics, Inc., formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners. In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions. The firm leverages strategic collaborations to expand its product offerings and enhance patient access. Research and development efforts are supported by a commercial infrastructure that provides sales, marketing and medical affairs support across various U.S. territories. Founded in 1995 as Depomed, the company rebranded to Assertio Therapeutics in late 2020 following a corporate restructuring designed to sharpen its focus on CNS disorders. Headquartered in Chicago, Illinois, Assertio operates a streamlined corporate structure to optimize efficiency and maintain healthy cash flows while pursuing growth through acquisitions and out-licensing opportunities. Its commercial reach is currently concentrated in North America, with plans to explore additional partnerships for international distribution. Assertio’s leadership team is led by President and Chief Executive Officer Donald P. Deieso, who has directed the company’s transformation and efforts to revitalize its portfolio. Under Deieso’s guidance, Assertio continues to prioritize disciplined resource allocation and strategic collaboration to drive product innovation and deliver value to patients, healthcare providers and shareholders.AI Generated. May Contain Errors. Read More Assertio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreASRT MarketRank™: Assertio scored higher than 41% of companies evaluated by MarketBeat, and ranked 652nd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingAssertio has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Assertio is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAssertio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Assertio's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3,600.00% Earnings GrowthEarnings for Assertio are expected to grow by 3,600.00% in the coming year, from $0.03 to $1.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.76% of the float of Assertio has been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 1.26, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assertio has recently increased by 0.71%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.39 News SentimentAssertio has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Assertio this week, compared to 3 articles on an average week.Search Interest18 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.MarketBeat Follows2 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have not sold or bought any company stock.Percentage Held by Insiders5.70% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASRT Stock News HeadlinesAssertio Agrees to Enhanced All-Cash Acquisition by GardaMay 20 at 12:53 PM | theglobeandmail.comAssertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRTMay 19 at 2:08 PM | businesswire.comSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of Treasuries are stepping back. That leaves the Fed with one real option: print. Gold is already trading around $4,500, but many miners are still priced as if gold were under $2,000. Garrett Goggin, CFA and CMT, has identified four miners positioned to close that gap. | Golden Portfolio (Ad)Assertio Therapeutics to be acquired by Zydus WorldwideMay 18, 2026 | tipranks.comAssertio Holdings (ASRT) price target decreased by 12.42% to 24.34May 14, 2026 | msn.comAssertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in CashMay 13, 2026 | finance.yahoo.comShareholder Alert: Ademi LLP investigates whether Assertio Holdings Inc. is obtaining a Fair Price for Public ShareholdersMay 13, 2026 | prnewswire.comAssertio and Garda Mutually Agree to Delay Launch of Tender OfferMay 8, 2026 | businesswire.comSee More Headlines ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $9.07 at the beginning of the year. Since then, ASRT stock has increased by 157.7% and is now trading at $23.37. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings results on Friday, May, 8th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.10) by $0.83. The company earned $9.93 million during the quarter, compared to the consensus estimate of $8.97 million. Assertio had a negative trailing twelve-month return on equity of 38.72% and a negative net margin of 34.94%. When did Assertio's stock split? Assertio's stock reverse split on Friday, December 26th 2025.The 1-15 reverse split was announced on Monday, December 22nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Assertio's major shareholders? Assertio's top institutional investors include Renaissance Technologies LLC (3.54%), Walleye Capital LLC (1.02%), Sei Investments Co. (0.85%) and Corsair Capital Management L.P. (0.40%). Insiders that own company stock include Daniel A Peisert, Heather L Mason, William Mckee, James L Tyree, Ajay Patel, Sam Schlessinger, Paul Schwichtenberg and Brendan P O'grady. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID). Company Calendar Last Earnings5/08/2026Today5/21/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ASRT's financial health is in the Green zone, according to TradeSmith. ASRT has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year Founded1995Price Target and Rating Average Price Target for Assertio$22.65 High Price Target$23.50 Low Price Target$21.80 Potential Upside/Downside-3.1%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($5.69) Trailing P/E RatioN/A Forward P/E Ratio779.00 P/E GrowthN/ANet Income-$30.38 million Net Margins-34.94% Pretax Margin-34.71% Return on Equity-38.72% Return on Assets-13.32% Debt Debt-to-Equity Ratio0.52 Current Ratio1.82 Quick Ratio1.57 Sales & Book Value Annual Sales$118.71 million Price / Sales1.27 Cash Flow$0.02 per share Price / Cash Flow1,433.62 Book Value$11.70 per share Price / Book2.00Miscellaneous Outstanding Shares6,460,000Free Float6,094,000Market Cap$150.97 million OptionableOptionable Beta0.44 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ASRT) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSneak Peek: Wall Street’s Little Black BookTom Busby, pro trader and CEO of the Diversified Trading Institute, spent years building a collection of what ...DTI Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
